Skip to main content
Premium Trial:

Request an Annual Quote

Compaq Seals Equipment Deal with Entelos

NEW YORK, Aug. 15 – Compaq has inked a three-year deal with biosimulation company Entelos to supply it with computer systems, the companies announced on Wednesday.

The deal calls for Entelos to purchase Compaq’s AlphaServer systems, which run Tru64 UNIX, and ProLiant servers, running Linux. The systems will serve as the computational platforms for Entelos’ in silico  disease simulator PhysioLab, which runs large-scale target-validation experiments incorporating physiologic systems, including proteomic and genomic-level analysis, involved in disease progression.

Financial details of the agreement were not disclosed. 

Entelos, based in Menlo Park, Calif., currently uses Sun Solaris systems. The Compaq deal includes adapting the new equipment for in-house use in addition to recommending the systems to Entelos’ customers, said an Entelos spokeswoman. 

“Entelos is providing different ways to look at drug targets and candidates,” Daniel Joy, business development manager at Compaq's Life Sciences Group, told GenomeWeb . “The real benefit is to weed out the failures before they get to the clinical trial stage. [Compaq] is working with companies to improve the efficiency of the drug pipeline by applying high-performance computing solutions,” he added.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.